MARKET

PHIO

PHIO

Phio Pharmaceuticals Corp
NASDAQ
6.60
+0.45
+7.32%
Closed 16:00 02/03 EST
OPEN
6.30
PREV CLOSE
6.15
HIGH
6.99
LOW
6.16
VOLUME
46.97K
TURNOVER
135.28K
52 WEEK HIGH
29.04
52 WEEK LOW
3.900
MARKET CAP
7.52M
P/E (TTM)
-0.6134
1D
5D
1M
3M
1Y
5Y
Phio Pharmaceuticals Has Received A Notice Of Allowance For Its U.S. Patent Application 16/680,101 Titled "RNA Duplexes With Single Stranded Phosphorothioate Nucleotide Regions For Additional Functionality (For Use In Gene Silencing)".
Benzinga · 01/26 18:49
Phio Pharma falls 10% on 1-for-12 reverse stock split
Seeking Alpha · 01/25 14:28
Phio Pharmaceuticals to Effect 1-for-12 Reverse Stock Split; Shares Decline
Phio Pharmaceuticals to Effect 1-for-12 Reverse Stock Split; Shares Decline
MT Newswires · 01/25 11:19
H.C. Wainwright Sticks to Their Buy Rating for Phio Pharmaceuticals (PHIO)
TipRanks · 01/09 16:05
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 01/09 13:05
Phio Pharmaceuticals Says US FDA Approves Clinical Trial With PH-762, AGX148 to Treat Solid Tumors
Phio Pharmaceuticals Says US FDA Approves Clinical Trial With PH-762, AGX148 to Treat Solid Tumors
MT Newswires · 01/06 15:23
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 12/26/2022 21:32
Phio Pharmaceuticals Outlines New PH-762 Program For Common Skin Cancer In US Patients
Benzinga · 12/22/2022 13:00
More
About PHIO
Phio Pharmaceuticals Corp. is a biotechnology company. The Company is focused on developing immuno-oncology therapeutics based on its self-delivering ribonucleic acid interface (RNAi) INTASYL therapeutic platform. Its INTASYL-based therapeutics are used to strengthen immune cells, for example those administered as part of adoptive cell therapy (ACT) and directly modify cells in the tumor microenvironment (the TME) to weaken a tumors defense. Its lead product candidate is PH-762, which is an INTASYL compound that activates immune cells to better recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1, a clinically validated target for immunotherapy. Its second product candidate, PH-894, is an INTASYL compound that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression that impacts cell differentiation, and hence, cell function. It is also developing PH-804, which targets the suppressive immune receptor TIGIT.

Webull offers kinds of Phio Pharmaceuticals Corp stock information, including NASDAQ:PHIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PHIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PHIO stock methods without spending real money on the virtual paper trading platform.